-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adakitug in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adakitug in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adakitug in Myelodysplastic Syndrome Drug Details: Adakitug (BMS-986253) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adakitug in Human Papillomavirus (HPV) Associated Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adakitug in Human Papillomavirus (HPV) Associated Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adakitug in Human Papillomavirus (HPV) Associated Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adakitug in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adakitug in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adakitug in Melanoma Drug Details: Adakitug (BMS-986253) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adakitug in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adakitug in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adakitug in Hormone-Sensitive Prostate Cancer Drug Details: Adakitug (BMS-986253) is...
-
Analyst Opinions
NewUnited Kingdom (UK) Personal Lines Insurance Distribution Dynamics and Future Market, 2023 Update
United Kingdom (UK) Personal Lines Insurance Market Report Overview The direct channel was the preferred choice for personal insurance purchases in the UK in 2023. Consumers are increasingly opting for online insurance purchases driving insurers and distributors to continue enhancing their online capabilities. Consumers prioritize affordability and trustworthiness when selecting an insurance provider, regardless of distribution channel. Hence, across all lines of distribution, the primary factors influencing consumers’ choice is either related to the cost of premiums or the provider’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium-188P2045 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium-188P2045 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium-188P2045 in Small-Cell Lung Cancer Drug Details: Rhenium-188P2045 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Garadacimab in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Idiopathic Pulmonary Fibrosis Drug Details: Garadacimab (CSL-312) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANV-419 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANV-419 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANV-419 in Renal Cell Carcinoma Drug Details: ANV-419 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANV-419 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANV-419 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANV-419 in Colorectal Cancer Drug Details: ANV-419 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANV-419 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANV-419 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANV-419 in Non-Small Cell Lung Cancer Drug Details: ANV-419...